Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

EyePoint Pharmaceuticals (EYPT) Total Current Liabilities: 2011-2019

Historic Total Current Liabilities for EyePoint Pharmaceuticals (EYPT) over the last 8 years, with Mar 2019 value amounting to $24.7 million.

  • EyePoint Pharmaceuticals' Total Current Liabilities rose 16.23% to $24.7 million in Q1 2019 from the same period last year, while for Mar 2019 it was $24.7 million, marking a year-over-year increase of 16.23%. This contributed to the annual value of $21.7 million for FY2018, which is 309.51% up from last year.
  • Per EyePoint Pharmaceuticals' latest filing, its Total Current Liabilities stood at $24.7 million for Q1 2019, which was up 14.91% from $21.5 million recorded in Q4 2018.
  • EyePoint Pharmaceuticals' Total Current Liabilities' 5-year high stood at $24.7 million during Q1 2019, with a 5-year trough of $2.2 million in Q1 2015.
  • For the 3-year period, EyePoint Pharmaceuticals' Total Current Liabilities averaged around $14.5 million, with its median value being $21.2 million (2018).
  • Its Total Current Liabilities has fluctuated over the past 5 years, first decreased by 13.74% in 2017, then soared by 423.91% in 2018.
  • Over the past 5 years, EyePoint Pharmaceuticals' Total Current Liabilities (Quarterly) stood at $3.9 million in 2015, then grew by 26.89% to $4.9 million in 2016, then decreased by 13.74% to $4.2 million in 2017, then spiked by 404.92% to $21.5 million in 2018, then rose by 16.23% to $24.7 million in 2019.
  • Its Total Current Liabilities stands at $24.7 million for Q1 2019, versus $21.5 million for Q4 2018 and $22.4 million for Q3 2018.